Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients... Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents TO THE EDITOR—We read with interest the recent study published by Van Hise and colleagues in which they evaluated the ef- ficacy of oral vancomycin prophylaxis (OVP) in preventing recurrent episodes of Clostridium difficile infection (CDI) in patients receiving systemic antimicro- bial therapy [1]. The authors performed a retrospective cohort study among pa- tients with a prior history of CDI and CORRESPONDENCE � CID 2016:63 (15 November) � 1391 subsequent antibiotic exposure and con- would result in overestimating the effect cluded that the receipt of OVP was asso- of OVP. ciated with a significantly lower risk of Last, the testing for recurrent C. diffi- C. difficile recurrence. These findings are cile was not blinded to the use of prophy- both important and timely given the bur- laxis. It is possible that differential testing den of CDI on our hospital systems and in the 2 arms was responsible for the dif- community. Indeed, the Centers for Dis- ferences. For example, testing in cases ease Control and Prevention (CDC) with noninfectious diarrhea may have states that prevention of CDI is a national been deferred http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Infectious Diseases Oxford University Press

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents

Loading next page...
 
/lp/oxford-university-press/efficacy-of-oral-vancomycin-in-preventing-recurrent-clostridium-o1RohV1l0i

References (2)

Publisher
Oxford University Press
Copyright
The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com
ISSN
1058-4838
eISSN
1537-6591
DOI
10.1093/cid/ciw595
pmid
27567123
Publisher site
See Article on Publisher Site

Abstract

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents TO THE EDITOR—We read with interest the recent study published by Van Hise and colleagues in which they evaluated the ef- ficacy of oral vancomycin prophylaxis (OVP) in preventing recurrent episodes of Clostridium difficile infection (CDI) in patients receiving systemic antimicro- bial therapy [1]. The authors performed a retrospective cohort study among pa- tients with a prior history of CDI and CORRESPONDENCE � CID 2016:63 (15 November) � 1391 subsequent antibiotic exposure and con- would result in overestimating the effect cluded that the receipt of OVP was asso- of OVP. ciated with a significantly lower risk of Last, the testing for recurrent C. diffi- C. difficile recurrence. These findings are cile was not blinded to the use of prophy- both important and timely given the bur- laxis. It is possible that differential testing den of CDI on our hospital systems and in the 2 arms was responsible for the dif- community. Indeed, the Centers for Dis- ferences. For example, testing in cases ease Control and Prevention (CDC) with noninfectious diarrhea may have states that prevention of CDI is a national been deferred

Journal

Clinical Infectious DiseasesOxford University Press

Published: Nov 15, 2016

There are no references for this article.